Vaccines based on historical virus isolates provide limited protection from continuously
evolving RNA viruses, such as influenza viruses or coronaviruses, which occasionally spill …

Since its emergence at the end of 2019, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has …

Background The safety and immunogenicity of the bivalent omicron-containing mRNA-
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …

Convergent evolution of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 lineages has led to
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

Booster vaccination for the prevention of Coronavirus Disease 2019 (COVID-19) is required
to overcome loss of protection due to waning immunity and the spread of novel severe acute …

Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized …

When to update COVID-19 vaccine composition | Nature Medicine Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …

SARS-CoV-2-specific T cell response has been proven essential for viral clearance, COVID-
19 outcome and long-term memory. Impaired early T cell-driven immunity leads to a severe …